New drug offers improved progression-free survival for melanoma patients

June 24, 2012

The drug was used to treat patients suffering from a form of advanced skin cancer, known as BRAF mutation-positive melanoma, and works by blocking a key signaling protein. Estimates suggest that there were approximately 46,000 deaths from melanoma in 2008, and while not all types of melanoma are suitable for treatment with dabrafenib, approximately 50% of melanomas carry the mutated form of the BRAF gene that allows the drug to work.

An international group of researchers, led by Dr Axel Hauschild of the Department of Dermatology, Schleswig-Holstein University Hospital in Kiel, Germany, compared dabrafenib's performance to the most commonly used existing treatment, dacarbazine (DTIC), in 250 patients suffering from spreading or inoperable BRAF-positive melanoma. 50% of the patients demonstrated a partial (47%) or complete response (3%) to the treatment in an independent review. By comparison, just 6% of patients treated with DTIC showed an improvement. Progression-free survival was also improved by the new drug, with the group of patients who received dabrafenib experiencing an average (median) progression-free survival time of 5.1 months, as compared to 2.7 months when treated with DTIC.

While dabrafenib is not the first drug of its kind, the new results suggest that it seems to have similar treatment efficacy and may have some advantages over the existing BRAF inhibitor, vemurafenib, which was recently approved by the US Food and Drug Administration (FDA) and the European Medicines Agency. In particular, the results suggest that the side effects of dabrafenib affecting the skin are less severe than those experienced by patients who are treated with vemurafenib, with the researchers noting that very few of the patients in this trial experienced serious side effects.

The small number of patient deaths over the course of the dabrafenib trial meant that the researchers were unable to assess the drug's effect on overall survival rates. In the light of good response and progression-free survival rates from a previous phase-2 trial ("BREAK-2"), patients with progressive disease under conventional DTIC treatment were allowed to receive dabrafenib, too. This cross-over design of the BREAK-3 trial may confound any conclusions on dabrafenib´s overall survival benefits.

Commenting on the paper, Dr Hauschild said: "This trial is good news for our patients with metastatic melanoma. Competition in the field is appreciated since it accelerates new clinical trials, particularly in the combinational setting. This trial is a major step forward in the run for an improvement of the survival for this disease, which was thought to be untreatable for decades".

Writing in a linked Comment on the paper, Professor Kim Margolin of the University of Washington said: "[this paper] joins the rapidly growing list of classic articles in this exciting discipline, where the rewards from scientific discovery are increasing benefits for patients with melanoma".
-end-
Dr Axel Hauschild, Schleswig-Holstein University Hospital, Germany T) +49 (0)431 597 1852 E) ahauschild@dermatology.uni.kiel.de or Dr Paul Chapman, Memorial Sloan-Kettering Cancer Center, New York, USA, T) +1 646 888 4162 E) chapmanp@mskcc.org

For interviews with Professor Kim Margolin, please contact Dean Forbes, Media Relations Manager, Fred Hutchinson Cancer Research Center, Seattle, USA, T) +1 206 6672896 E) dforbes@fhcrc.org

Lancet

Related Melanoma Articles from Brightsurf:

Boosting treatments for metastatic melanoma
University of Cincinnati clinician-scientist Soma Sengupta, MD, PhD, says that new findings from her and Daniel Pomeranz Krummel's, PhD, team might have identified a treatment-boosting drug to enhance effectiveness of therapies for metastatic cancer and make them less toxic, giving patients a fighting chance at survival and improved quality of life.

A promising new tool in the fight against melanoma
An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.

New targets for melanoma treatment
A collaborative study led by Monash University's Biomedicine Discovery Institute and the Olivia Newton-John Cancer Research Institute (ONJCRI) has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma.

Innovative smartphone-camera adaptation images melanoma and non-melanoma
An article published in the Journal of Biomedical Optics (JBO), ''Point-of-care, multispectral, smartphone-based dermascopes for dermal lesion screening and erythema monitoring,'' shows that standard smartphone technology can be adapted to image skin lesions, providing a low-cost, accessible medical diagnostic tool for skin cancer.

Antihistamines may help patients with malignant melanoma
Can a very common allergy medicine improve survival among patients suffering from the serious skin cancer, malignant melanoma?

Blood test for deadly eye melanoma
A simple blood test could soon become the latest monitoring tool for the early detection of melanoma in the eye.

Analysis of melanoma in US by age groups
This study used registry data to determine annual rates of melanoma in pediatric, adolescent, young adult and adult age groups, and the findings suggest an apparent decrease among adolescent and young adults between 2006 and 2015 but increases in older adults.

Vitamin D dials down the aggression in melanoma cells
Vitamin D influences the behaviour of melanoma cells in the lab by making them less aggressive, Cancer Research UK scientists have found.

B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer.

Five things to know about melanoma
'Five things to know about ... melanoma' in CMAJ (Canadian Medical Association Journal) provides a brief overview of this malignant skin cancer for physicians and patients.

Read More: Melanoma News and Melanoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.